GLP-1 Tirzepatide Cost: What Private Treatment Actually Includes

What UK private tirzepatide actually costs, and why the range is so wide

The first thing worth knowing: prices shifted significantly in late 2025. Eli Lilly raised Mounjaro's UK list price from 1 September 2025, with the highest dose's list price moving from around £122 to around £330 per four-week pen. That increase fed through to private providers at different speeds and in different ways, which is one reason you'll see quotes ranging from around £149 to £375 a month depending on dose and service. If you want a fuller breakdown of how those figures are structured, our page on Mounjaro GLP-1 cost walks through the components in detail.

The other reason the range is wide is dose. Tirzepatide treatment starts at 2.5mg (a tolerability dose, not the maintenance level) and is titrated upward by the prescriber, typically in four-week steps, toward a dose your body and your goals suit. Higher doses carry higher list prices, so the monthly cost you pay later in treatment is likely to differ from what you paid at the start. You can find dose-specific context for the 5mg stage and the 10mg stage if you want to plan ahead.

One misconception worth setting aside gently: some people assume the price is mainly for the pen itself, with the clinical bits tacked on. It's actually the reverse. The medicine's list price is public; what differs between providers is how much clinical infrastructure surrounds it. According to NICE's appraisal of tirzepatide (TA1026), this medicine is recommended as part of a managed weight programme, not as a standalone product. The cost of safe, supervised treatment reflects that.

What headline prices often leave out

A quoted monthly figure can legally cover different things with different providers. Some charge separately for the initial consultation. Others add a prescription fee per issue. Delivery (sometimes refrigerated, tracked, requiring a safe-drop arrangement) may be invoiced separately. Aftercare, dose-review support, and access to a prescriber between orders are sometimes not included at all, or are offered only at a higher tier.

None of this is a complaint about how others operate. It's a practical point: when you compare two monthly figures, you may be comparing different bundles. The NHS England guidance on weight management injections is clear that clinical oversight and lifestyle support are expected alongside the medicine, costs that have to sit somewhere.

At nume, one price covers consultation, prescription, treatment, delivery and ongoing support. We're not the cheapest option in the market, and that's a deliberate choice rather than an oversight. What that price buys is a single bill with nothing added later. Current treatment pricing is shown on our treatment page, where you can also start your consultation.

Whether the NHS route changes the calculation

NHS access to tirzepatide is real but currently phased. NICE recommended tirzepatide (TA1026, published December 2024) for adults with a BMI of 35 or above and at least one weight-related condition. NHS England's rollout began in June 2025 for those with a BMI of 40 or above plus four or more qualifying conditions, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. Cohort 2 (BMI 35–39.9, four or more conditions) was activated in June 2026. If you qualify and your GP practice is participating, the medicine is available on prescription.

If you don't meet the current NHS thresholds, or your practice isn't yet set up to prescribe, or you'd rather not wait, private treatment through a GPhC-registered pharmacy is the legal alternative. There's no referral required, no waiting list at nume, just a clinical consultation followed by same-day review. Our about us page explains how we're regulated, and you can verify our pharmacy registration directly on the GPhC register (9012878).

Why price is the wrong test for a prescription medicine

Tirzepatide pens look identical. That makes it tempting to treat them as a commodity and pick the cheapest listing. The MHRA has warned repeatedly about counterfeit weight-loss pens sold through unverified online sellers, fake pens have contained insulin, and enforcement in 2025 included approximately 20 million doses of illegally traded weight-loss medicines (~£45m street value) seized, and the first illicit UK manufacturing site for counterfeit tirzepatide raided. The MHRA's Yellow Card scheme exists partly so people can report suspect sellers.

A low price from an unverified seller isn't a bargain, it's a signal. Legitimate supply in the UK means a registered pharmacy, a GPhC-registered prescriber who reviews your case personally, and medicine sourced through the licensed UK supply chain. None of that infrastructure is free, which is why our page covering tirzepatide cost explains what legitimate private pricing typically includes and why the numbers look the way they do. If you're specifically approaching the upper end of the titration schedule, you can also read about what the 15mg dose costs and what factors influence that figure. A saving of £20 a month answers the wrong question if what's missing is the clinical oversight that keeps you safe.

If you'd like to understand more about how Mounjaro works as a treatment before thinking about cost, or if you're ready to find out whether you're eligible, our prescribers are the right next step. You can also read the broader weight-loss treatment overview for context on what supervised GLP-1 treatment involves.